Editas Medicine(NASDAQ) EDIT

Current Price$2.61

Market Cap$399.00M

Since IPO (2016)-86%

5 Year-94%

1 Year-20%

1 Month-7%

Editas Medicine last closing stock price
Metric	Price	Date
Last close	USD 2.60	2026-07-24

Editas Medicine stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-12.75%	USD 2.98	2026-07-17
1 month	-7.14%	USD 2.80	2026-06-24
3 month	-10.65%	USD 2.91	2026-04-24
Year to date	+26.83%	USD 2.05	2025-12-31
1 year	-20.25%	USD 3.26	2025-07-24
3 year	-69.98%	USD 8.66	2023-07-25
5 year	-93.63%	USD 40.84	2021-07-23
Since inception	-85.71%	USD 18.20	2016-02-03

Editas Medicine Financials at a Glance

Market Cap

$399.00M

Revenue (TTM)

$38.69M

Net Income (TTM)

-$108.95M

EPS (TTM)

-$1.22

P/E Ratio

-2.13

Dividend

$0.00

Beta (Volatility)

2.10 (High)

Dividend

$0.00

Beta (Volatility)

2.10 (High)

Price

$2.61

Volume

1,516,741.224

Open

$2.75

Price

$2.61

Volume

1,516,741.224

Open

$2.75

Previous Close

$2.60

Daily Range

$2.59 - $2.76

52-Week Range

$1.66 - $4.54

Estimated Earnings Date

Aug 11, 2026

Dividend

$0.00

Beta (Volatility)

2.10 (High)

Price

$2.61

Volume

1,516,741.224

Open

$2.75

Previous Close

$2.60

Daily Range

$2.59 - $2.76

52-Week Range

$1.66 - $4.54

Estimated Earnings Date

Aug 11, 2026

EDIT News

CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?

Robert IzquierdoMay 31, 2026

DNA with a section separated from the main part.

Page 1

EDIT: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Editas Medicine

Editas Medicine makes medicines that fix broken genes. These treatments help people with rare and serious illnesses. The company uses CRISPR tools to edit genetic code.

The Pipeline and Licensed Tools

Hyperlipidemia Therapy: Experimental treatment called EDIT-401 designed to lower high cholesterol levels in the blood.
Hematopoietic Stem Cells: Research focused on editing blood-forming cells to treat various genetic conditions.
Licensed Technologies: Cas9 gene editing technology used by other companies to develop treatments for sickle cell disease.
Oncology Research: Engineered cell medicines developed with partners to target different types of cancer.

New Strategies and Major Shifts

Entered a license agreement with Vertex Pharmaceuticals in December 2023 for Cas9 gene editing technology.
Amended a collaboration with Bristol-Myers Squibb in March 2024 to extend research efforts through 2026.
Formed a strategic alliance with DRI Healthcare Acquisitions LP in October 2024 to sell future revenue rights.
Discontinued clinical development of the reni-cel program in December 2024 to focus on internal research.

Innovation Inside the Body

Editas focuses on in vivo gene editing which fixes genes directly inside the human body. This approach avoids the need to remove and replace cells in a laboratory.

A Look at the Numbers

Revenue hit $2.8 million in Q1 2026, down 39.2% from $4.7 million in Q1 2025.
Net loss narrowed to $25 million in Q1 2026, improved from $76.1 million in Q1 2025.
Operating cash flow reached negative $23.1 million in Q1 2026, improved from negative $47.8 million in Q1 2025.
Cash and cash equivalents totaled $123.6 million as of March 31, 2026.

Bottom Line

Editas has shifted from broad clinical development to a focused strategy on in vivo genomic medicines. Its transition includes significant workforce reductions and a reliance on technology licensing to fund its lead research programs.

AI Generated • May 19, 2026

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Gilmore O’Neill, MD

Website

www.editasmedicine.com

Headquarters

Cambridge, MA 02141, US

EDIT Financials

Key Financial Metrics (TTM)

Gross Margin

5.83%

Operating Margin

-297.50%

Net Income Margin

-281.59%

Return on Equity

-677.39%

Return on Capital

-95.52%

Return on Assets

-72.96%

Earnings Yield

-46.95%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$399.00M

Shares Outstanding

153.46M

Volume

1.52M

Avg. Volume

2.49M

Financials (TTM)

Gross Profit

$2.25M

Operating Income

-$115.11M

EBITDA

-$100.08M

Operating Cash Flow

-$140.50M

Capital Expenditure

-$585.00K

Free Cash Flow

-$141.09M

Cash & ST Invst.

$123.65M

Total Debt

$71.97M

Editas Medicine Performance Analysis

Editas Medicine annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 19,712,000	-22.8%
2023	2023-12-31	USD 78,123,000	296.3%
2024	2024-12-31	USD 32,314,000	-58.6%
2025	2025-12-31	USD 40,520,000	25.4%

Editas Medicine sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	-23.2%
Q3	2025-09-30	110.8%
Q4	2025-12-31	228.0%
Q1	2026-03-31	-88.6%

Editas Medicine annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -3.21	12.8%
2023	2023-12-31	USD -2.02	-37.2%
2024	2024-12-31	USD -2.88	42.8%
2025	2025-12-31	USD -1.80	-37.4%

Editas Medicine sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	31.5%
Q3	2025-09-30	55.6%
Q4	2025-12-31	79.4%
Q1	2026-03-31	-349.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$2.83M

-39.2%

Gross Profit

$2.35M

+110.7%

Gross Margin

82.94%

N/A

Market Cap

$399.00M

N/A

Market Cap/Employee

$4.59M

N/A

Employees

N/A

Net Income

-$24.98M

+67.2%

EBITDA

-$23.43M

+67.4%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$123.65M

-44.0%

Total Debt

$71.97M

+131.2%

Accounts Receivable

$2.59M

+408.2%

Inventory

$0.00

N/A

Long Term Debt

$57.78M

+221.5%

Short Term Debt

$14.20M

+7.9%

Return on Assets

-72.96%

N/A

Return on Invested Capital

-1.05%

N/A

Free Cash Flow

-$23.15M

+51.7%

Operating Cash Flow

-$23.06M

+51.8%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

AVIRAtea Pharmaceuticals, Inc.

AVIRAtea Pharmaceuticals, Inc.$4.73-0.42%

CABACabaletta Bio, Inc.

CABACabaletta Bio, Inc.$2.69-1.10%

KYTXKyverna Therapeutics, Inc.

KYTXKyverna Therapeutics, Inc.$7.41+1.65%

VNDAVanda Pharmaceuticals Inc.

VNDAVanda Pharmaceuticals Inc.$5.18-3.36%

LYELLyell Immunopharma, Inc.

LYELLyell Immunopharma, Inc.$12.63-1.17%

ALLOAllogene Therapeutics, Inc.

ALLOAllogene Therapeutics, Inc.$1.74-4.40%

VYGRVoyager Therapeutics, Inc.

VYGRVoyager Therapeutics, Inc.$3.10+0.32%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NOKNokia

NOKNokia$9.10-0.06%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.42-0.04%

ONDSOndas

ONDSOndas$7.80-0.02%

NUNu Holdings

NUNu Holdings$14.09-0.01%

FFord Motor Company

FFord Motor Company$14.37+0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$14.48+0.07%

CLFCleveland-Cliffs

CLFCleveland-Cliffs$11.93+0.09%

Questions About EDIT

What is the current price of Editas Medicine?

Editas Medicine is trading at $2.60 per share.

What is the 52-week range for Editas Medicine?

Over the past 52 weeks, Editas Medicine has traded between $1.66 and $4.54.

How much debt does Editas Medicine have?

As of the most recent reporting period, Editas Medicine reported total debt of $71.97M.

How much cash does Editas Medicine have on hand?

Editas Medicine reported $123.65M in cash and cash equivalents in its most recent financial results.

What is Editas Medicine’s dividend yield?

Editas Medicine does not currently have a dividend yield.

Editas Medicine(NASDAQ) EDIT

Editas Medicine Financials at a Glance

EDIT News

CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?

Best CRISPR Gene Editing ETFs for 2026 and How to Invest

Is Editas Medicine Going to $0?

Why Editas Medicine Stock Was Skyrocketing This Week

Can This Beaten-Down Stock Bounce Back?

Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now?

2 Beaten-Down Stocks to Avoid

Editas Medicine Is Great. Here's Why You Shouldn't Buy It.

EDIT: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Editas Medicine

The Pipeline and Licensed Tools

New Strategies and Major Shifts

Innovation Inside the Body

A Look at the Numbers

Bottom Line

EDIT Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Editas Medicine Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About EDIT

What is the current price of Editas Medicine?

What is the 52-week range for Editas Medicine?

How much debt does Editas Medicine have?

How much cash does Editas Medicine have on hand?

What is Editas Medicine’s dividend yield?

Premium Investing Services